Beam Therapeutics (BEAM) – Market Activity Overview
- Current Price: USD 23.84
- Trading Session: 24‑hour period ending 06:53 PM Central Europe, Friday 23 Dec 2026
- Price Change: Down 0.36 %
- Shares Outstanding: 103.3 million
- Market Capitalisation: USD 2.6 billion
- Volume (last 24 h): Approximately USD 29 million worth of shares traded
- Month‑End Performance: Down 4.2 % since the end of the previous month
- 200‑Day Simple Moving Average: USD 28.31
- 52‑Week High: USD 38.26 (07 Jul 2026)
- 52‑Week Low: USD 20.23 (20 Nov 2025)
Recent Performance of Related Stocks (24‑Hour Period)
| Symbol | Company | Price | % Change | Market Cap | P/E Ratio | Notable Events |
|---|---|---|---|---|---|---|
| HTGC | Hercules Capital | USD 16.39 | +1.35 % | USD 3.1 billion | 8.09 | — |
| MARA | Mara | USD 7.24 | -6.93 % | USD 3.0 billion | — | CFO Salman Khan sold shares under a Rule 10b5‑1 plan; ownership by his family trust remains substantial. |
| NMIH | Nmi | USD 42.67 | +1.77 % | USD 3.1 billion | 8.02 | — |
| FHB | First Hawaiian | USD 25.24 | +3.16 % | USD 3.1 billion | 11 | Reported Q3 2026 earnings with modest net income increase, higher net interest margin, and a quarterly dividend of $0.26 per share. |
| ELVN | Enliven Therapeutics | USD 41.40 | +1.38 % | USD 3.1 billion | — | Two Form 4 filings disclosed senior officer trades under Rule 10b5‑1 plans, including purchases and sales of common stock and stock options. |
Company Background
Beam Therapeutics Inc. is a biotechnology company focused on developing DNA base‑editing technologies for the treatment of human diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq exchange. Further information about Beam Therapeutics’ products and initiatives is available on its website: www.beamtx.com .
